NWPharmaTech @NWPharmaTech

Two separate routes (newsletter is never required for financing): 1) Programme news → Contact → Programme updates — Register for programme updates 2) Exploratory financing conversation → Contact → Financing enquiry — Express interest in programme financing Before either: read how catalytic capital could be used (informational planning only): nwpharmatech.org/funding-use Not an offer. Not medical advice. You cannot invest, pay, or connect a wallet on our website. Community follow ≠ investment entitlement. Next step → Funding-use + discuss programme financing via Contact. nwpharmatech.org/funding-use nwpharmatech.org/contact

keyboard_arrow_left Previous keyboard_arrow_right Next

What NWPharmaTech is — and is not. We are a clinical-stage biotech. Lead programme NWPT-SM32300 is an investigational cannabidiol research programme for people at clinical high risk of psychosis. Effectiveness is not established. Prevention is not the current primary aim of the proposed next study. Phase 1 unpublished. Next study proposed / not recruiting. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → Science: nwpharmatech.org/science Evidence library: nwpharmatech.org/evidence

keyboard_arrow_left Previous keyboard_arrow_right Next

What NWPharmaTech is — and is not. We are a clinical-stage biotech. Lead programme NWPT-SM32300 is an investigational cannabidiol research programme for people at clinical high risk of psychosis. Effectiveness is not established. Prevention is not the current primary aim of the proposed next study. Phase 1 unpublished. Next study proposed / not recruiting. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → Science: nwpharmatech.org/science Evidence library: nwpharmatech.org/evidence

keyboard_arrow_left Previous keyboard_arrow_right Next

CHR-P is not a diagnosis of schizophrenia. The public Science pages explain the clinical questions, how cannabinoid research programmes differ in framing, and what remains open for our investigational candidate NWPT-SM32300. We do not claim established effectiveness in this population. Prevention is not the current primary aim of the proposed next study. Illustrations are conceptual — not mechanism proof. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → nwpharmatech.org/science

What programme financing — if raised through proper private channels — is meant to advance: Illustrative planning toward a proposed Phase 2B (not recruiting): clinical preparation, trial operations, product supply, regulatory readiness, analysis path, contingency. Planning figures stay in private diligence — not money already raised, not a priced offer on this site. Effectiveness not established. Prevention not the current primary aim. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. → Funding-use: nwpharmatech.org/funding-use To discuss programme financing (enquiry only): Contact → Express interest in programme financing. nwpharmatech.org/contact

People behind the work (roles, not institutional endorsements of this website or any financing vehicle): • Professor Scott Woods — CHR-P programme lead (individual capacity). Yale University does not sponsor or endorse this website, the DAO, or any financing vehicle. • Dr Grace Blest-Hopley — Partner & Chief Scientific Officer • Dr John Kane, MD — Lead, Schizophrenia Programme Programme is investigational. Effectiveness not established. Prevention not the current primary aim of the proposed next study. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → Science (leadership + programme context): nwpharmatech.org/science

What our public evidence frame does — and does not — establish. Does: separates investigational status, open questions, and sources you can check. Does not: establish effectiveness in CHR-P. Does not make prevention the current primary aim of the proposed next study. Does not claim Phase 1 results (unpublished). Next study is proposed / not recruiting. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → Science: nwpharmatech.org/science (Also: Evidence library nwpharmatech.org/evidence)

keyboard_arrow_left Previous keyboard_arrow_right Next

The research question we are actually asking: In people at clinical high risk for psychosis (CHR-P), what does a carefully designed study of investigational NWPT-SM32300 (our cannabidiol research programme) need to learn about dose response, symptoms, safety and tolerability? Effectiveness in CHR-P is not established. Prevention is not the current primary aim of the proposed next study. Not medical advice. Not an offer. You cannot invest, pay, or connect a wallet on our website. Next step → Science: nwpharmatech.org/science

Short orientation on the endocannabinoid system in our research context. Investigational programme. Effectiveness not established. Prevention not the current primary aim of the proposed next study. Not medical advice. Not an offer. nwpharmatech.org/evidence